UroGen Pharma Ltd. (URGN) is a Healthcare stock trading at $46.85 (as of 2026-08-21), with a market capitalization of $2.28B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing treatments for specialty cancers and urothelial diseases. Its portfolio includes RTGel and Jelmyto, with clinical-stage candidates such as UGN-102 and UGN-301, and partnerships/agreements supporting development and commercialization activities in urinary tract cancers.
Understand UroGen Pharma Ltd.: how it makes money
UroGen Pharma develops and commercializes specialty cancer and urothelial disease treatments, including RTGel-based therapies such as Jelmyto, and it makes money by selling these products as product revenue.
The profit model depends on translating clinical and commercialization execution for specific urothelial cancer products, where revenue is built from product uptake across activated sites and the successful progression of key candidates like UGN-102 in Phase III.
Revenue by segment (latest quarter)
Gelmido
$0.0B
ZUSDURI
$0.0B
Jelmyto
$0.0B
Gelmito
$0.0B
Zesturi
$0.0B
Business quality (Solid): High gross margin on reported revenue, but the company is still loss-making on an operating basis, and the lead product candidate remains in Phase III.
Bull case
Product revenue exists across multiple urothelial cancer therapies (Gelmido, ZUSDURI, Jelmyto, Gelmito, Zesturi): This suggests the commercialization engine is already running rather than being purely pre-revenue.
High reported gross margin of 91.9% for the latest quarter provided: A high gross margin can indicate strong unit economics if product demand and mix hold up.
Clinical readouts for UGN-102 in the provided data show favorable signals, including a hazard ratio of 0.45 and ATLAS disease-free survival risk reduction of 55%: Positive efficacy signals can support confidence in the Phase III program, which is central to longer-term value creation.
Commercial footprint metrics are present, including 838 Activated Sites of Care and 2,000 Early Adopter Physicians (provided): Expansion of treated access and prescriber adoption can help support future product demand.
Bear case
Operating margin is -39.8% in the latest quarter provided: The company is not yet profitable at the operating level, so continued execution and cost control matter.
The lead product candidate UGN-102 is still in Phase III clinical trials: Phase III outcomes, timelines, and potential path to commercialization are uncertain.
Key clinical metrics shown are trial-related (for example, complete response rates at three months and hazard ratio): Trial success may not directly guarantee commercial performance, pricing, reimbursement, or uptake.
Commercial funnel metrics are provided (for example, Activated Sites of Care, Early Adopter Physicians, conversion time), but the link from these metrics to sustained revenue is not quantified in the provided data: Without demonstrated conversion into durable product revenue, commercialization progress may not translate into improved profitability.